Contact Us marketing@medicilon.com
CN
×
Close Button
FAQs

Why is Early DMPK Important?

In 1991, up to 40% of failures in the clinical phase of new drug development were associated with drug DMPK properties; in 2000, the likelihood of late failure was dramatically reduced to less than 10% as major pharmaceutical companies shifted to early DMPK studies.

(1) Early pharmacokinetic testing allows for a low-cost, short-term risk-benefit assessment of new drug development projects.

(2) Guiding the processes from optimization of lead compounds to determination of preclinical drug candidates.